Table 2 List of studies for the applications of rhMG53 in the management and treatement of heart diseases

Han et al. [44]

Sepsis-induced myocardial dysfunction in rats

5 mg/kg; i.v.; 120 min post surgery.

Increased the survival rate with improved cardiac function, and reduced oxidative stress, inflammation, and myocardial apoptosis

Upregulation of PPARα signal pathway

Liu et al. [68]

I/R-induced acute MI in both mice and porcine

1.0 mg/kg; i.v.; prior to ischemia, or 2, 30 min post reperfusion.

Reduced infarct size and troponin I

Release, improved cardiac structure and function.

Activation of Akt/GSK3β pathway.

Shan et al. [18]

I/R induced MI w/wo IPC in both mouse and rats

For rats: 3 mg/kg, i.v.; two dose: 5 min prior ischemia and post reperfusion; For mice: 6 mg/kg, i.v.; 40 min before IPC.

Decreased the infarct Size; reduced mortality; decreased cardiac apoptosis, and blood LDH level; Increased LV-EF.

Activation of PKCδ

Wang et al. [60]

Wild type rats

1, 10, and 40 mg/kg; i.v.; every 2 days for a 14-day period

Administration of rhMG53 did not altered insulin signaling and glucose handling

N/A